Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

31 May 2018: Articles  Japan

A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions

Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Adverse events of drug therapy

Haruka Hirono ABCDEFG 1*, Kazuhiko Watanabe D 1, Katsuhiko Hasegawa D 1, Terasu Honma D 2, Yoichi Ajioka BD 3, Shogo Ohkoshi ACDEFG 1

DOI: 10.12659/AJCR.909644

Am J Case Rep 2018; 19:623-629

0 Comments

Abstract

BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease, affecting the colon continuously from the rectum proximally. However, a clinical type with right-sided colitis sparing the anal side of the colon is also known. Mesalamine, which is generally used to treat UC, can rarely aggravate the disease.

CASE REPORT: A 56-year-old woman with no history of colonic diseases visited our hospital because of a positive fecal occult blood test. The first colonoscopy showed inflamed and edematous mucosa extending from the ascending colon to the right-half of the transverse colon. Colonic biopsy specimens demonstrated infiltrations of chronic inflammatory cells in the mucosa and crypt abscesses, but no epithelioid granulomas, compatible with UC. She was highly positive for PR3-ANCA, confirming the diagnosis of UC. After starting mesalamine, she had hypersensitivity reactions and aggravations of UC, which were confirmed endoscopically.

CONCLUSIONS: Right-sided colitis may be a subgroup of UC, and this is the first report of this type of disease complicated by aggravation due to mesalamine hypersensitivity.

Keywords: Antibodies, Antineutrophil Cytoplasmic, Colitis, Ulcerative, Colon, Ascending, Drug Hypersensitivity, Mesalamine

Background

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory bowel disease in which the inflammation is mainly located in mucosal layers, affecting the bowel continuously from the rectum to the proximal side [1,2]. The Montreal classification divides the extent of UC into 3 types: E1 (proctitis), E2 (left-sided; distal), and E3 (pancolitis) [2]. However, it has been known that some patients with proctitis or left-sided colitis have a cecal patch of inflammation [3,4], and UC with right-sided or segmental colitis with no recto-sigmoid inflammation has been reported [5,6]. Mesalamine and other 5-aminosalicylic acid (5-ASA) compounds are mainstay drugs for induction and maintenance treatment of UC because of their safety and usefulness [7]. However, it is known that mesalamine-induced hypersensitivity reactions can occur and cause aggravation of UC [8,9]. In this report, a case of UC that presented with right-sided colitis complicated by aggravation due to mesalamine-induced hypersensitivity reactions is described. Moreover, changes in the endoscopic findings of mesalamine-induced hypersensitivity reactions are also presented.

Case Report

A 56-year-old woman with no history of UC visited our hospital because of a positive fecal occult blood (FOB) test. She had felt vague discomfort in her upper abdomen for the past few years. However, she had no bloody mucoid diarrhea, abdominal pain, or fever. On examination, there were no abdominal findings except for mild tenderness of the right upper quadrant. Routine laboratory tests were normal other than slight elevation of inflammatory markers, with the erythrocyte sedimentation rate (ESR) at 58 mm/h and C-reactive protein (CRP) of 0.47 mg/dL. The first colonoscopy showed that inflamed and edematous mucosa was confined from the ascending to the right-half of the transverse colon, with mucosal friability, multiple shallow ulcerations, erosions, erythema, and loss of typical vascular patterns (Figure 1). Patchy inflammation in other lesions or backwash ileitis was not seen. There were no significant bacteria on stool culture results. Colonic biopsy specimens of the inflamed mucosa demonstrated infiltrations of chronic inflammatory cells in the lamina propria, cryptitis, crypt abscesses, and architectural distortions, but there were no epithelioid granulomas, which were pathologically compatible with UC (Figure 2). The rectum and left-sided colon with intact colonoscopic findings did not show any inflammation on histological examination (data not shown).

Therefore, the right-sided colitis type of UC was diagnosed. The activity of UC was evaluated by the Mayo scoring system [10], which resulted in a score of 3. Mesalamine (Asacol® tablets; Tillotts Pharma AG, Ziefen, Switzerland) at 2400 mg/day was then started (Figure 3). However, approximately 1 week later, a slight fever occurred, and it increased to over 39°C in an intermittent manner. Exacerbation of the diarrhea and abdominal pain did not occur. She was admitted to our hospital 16 days after the start of mesalamine treatment. Although physical examination on admission only showed high fever and mild tenderness of the right upper quadrant, as at the first examination, no other abdominal symptoms or drug allergy findings such as a skin rash could be seen. Blood examinations showed higher levels of inflammation markers, with the ESR at 119 mm/h and a CRP of 18.3 mg/dL. Eosinophilia was not observed (4% of 5.73×109/L white blood cells). However, liver and pancreatic enzyme levels were normal. With a normal level of serum procalcitonin and negative results on blood culture and for cytomegalovirus (CMV) antigenemia, infections were ruled out. Although anti-nuclear antibody (ANA) and myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) were negative, proteinase-3 ANCA (PR3-ANCA) was positive (55.2 U/mL, CLEIA method, SRL Inc, Tokyo, Japan). Primary sclerosing cholangitis (PSC) was not seen on magnetic resonance cholangiopancreatography (MRCP). On the basis of these results, mesalamine-induced hypersensitivity reactions were suspected. A lymphocyte transformation test (LTT) for mesalamine showed a positive result (220 cpm, 207%; control 106 cpm). Therefore, the diagnosis was right-sided or segmental colitis type UC with mesalamine-induced hypersensitivity reactions. Mesalamine treatment was immediately withdrawn, and a second colonoscopy was performed (Figure 4). It showed more intensely inflamed mucosa at the same inflamed colonic segments as at the first colonoscopy, from the ascending colon to the right-half of the transverse colon, with more edematous mucosa, bowel stenosis, and much more purulent erosions and ulcerations. In addition, mucosal inflammation expanded toward the oral and anal sides. Scattered erosions appeared in the cecum and around the appendiceal orifice and in the left-half of the transverse colon. However, the left-sided colon from the descending colon to the rectum showed no inflammation, as before. Histopathologic examination of biopsy specimens of the inflamed mucosa showed more severe inflammation (data not shown). After drug withdrawal, the high fever and inflammatory findings disappeared promptly. Only probiotics including Bifidobacterium longum and infantis were then prescribed. After discharge, the patient still felt vague discomfort of her right upper abdomen. Three months after withdrawal of mesalamine treatment, a third colonoscopy was done as follow-up (Figure 5). It showed that the inflamed mucosa was again restricted from the ascending colon to the right-half of the transverse colon, and the inflammation of the mucosa was ameliorated; the edematous mucosa and the bowel stenosis of the inflamed colonic segment were improved, the ulcerations of the ascending colon had improved and changed to multiple ulcer scars, and the purulent erosions and shallow ulcerations had improved. Scattered erosions at the cecum and the left-half of the transverse colon, appearing at the second colonoscopy, were no longer seen. The border between the inflamed and non-inflamed mucosa at the right-side of the transverse colon became clear because the edematous mucosa improved. After the third colonoscopy, oral prednisolone (PSL) was started at 30 mg/day along with 6-mercaptopurine (6-MP) at 30 mg/day, in addition to the probiotics, and the dose of PSL was tapered over a period of 1 year (Figure 3). A fourth colonoscopy was done after nearly 3 months of combination therapy with PSL and 6-MP (Figure 6). It showed that the edema of the inflamed mucosa from the ascending to the right-half of the transverse colon had improved even more and disappeared, resulting in multiple reticular scars. The active erosions and ulcers were not seen, but instead, the regenerating epithelium was seen at the same colonic segment. The border between the inflamed and non-inflamed mucosa at the right-side of the transverse colon could be seen more clearly. The inflammatory markers of UC were also improved, with ESR at 17 mm/h and CRP of 0.03 mg/dL. The patient has maintained her good general condition since she was discharged from the hospital.

Discussion

UC is a chronic inflammatory disease characterized by involvement of the rectum with extension to the proximal colon in a continuous manner. On the other hand, involvement of the appendiceal orifice as a discontinuous lesion is well known [3,4]. In Japan’s diagnostic and therapeutic guidelines in 2017, the right-sided or segmental type of UC is classified as one disease type along with total, left-sided colitis, and proctitis. It is considered to be a subtype of UC in which the anal side is spared. So far, this subtype has been described in very few reports from Western countries [5]. Although the cause of this discrepancy has not been well elucidated, the subgroup of patients with an uncertain diagnosis has been classified as “indeterminate colitis”[11]; it accounts for about 5% of inflammatory bowel disease (IBD) cases in Japan [12]. The present case could be classified into this type of IBD because of the atypical location of the colonic lesion. However, while the colonic lesion was restricted to the right side of the colon, it was continuous. There were no lesions suggestive of Crohn’s disease, such as longitudinal ulcers and a cobblestone appearance. Moreover, the histological lesions showed typical features of UC, without any granulomatous lesions. Given these findings, UC was diagnosed in this patient.

ANCAs are the most frequently studied serological markers for IBD [13]. A combination of both tests could help make the diagnosis of inflammatory bowel disease. The present case was negative for MPO-ANCA, which constitutes a large part of P-ANCA, but was positive for PR3-ANCA, which targets the serine protease proteinase-3 [14]. Several studies reported that PR3-ANCA positivity was useful in differentiating UC from CD [15]. In particular, Arias-Loste et al. reported that a cut-off PR3-ANCA titer of 11.8 chemiluminescent units showed 97.3% specificity for UC (it was 55.2 in the present case), strongly supporting the diagnosis of UC in the present patient [16]. Although PR3-ANCA is frequently detected in primary sclerosing cholangitis [17], this disease was not detected with MRCP.

Our patient was diagnosed at a regular health screening with the FOB test. Howarth et al. investigated subjects who were found to be FOB-positive on screening for colorectal cancer. Among 44 838 cases, 52 were previously undetected UC, for an estimated rate of 116 per 100 000 (95%CI=85–147/105), and 17% (9/52) was asymptomatic. Among them, 52% (27/52) had only proctosigmoiditis, and 25% (13/52) had total colitis. However, the right-sided or segmental colitis type of UC was not found [18]. On the other hand, among 236 000 healthy Japanese who underwent FOB test screening, 19 were diagnosed as having asymptomatic or minimally symptomatic UC on colonoscopy, and 4 had asymptomatic right-sided or segmental type [19]. These studies suggested that UC, including right-sided or segmental colitis type, can exist in healthy individuals.

Another important aspect of this patient was aggravation of the colitis by hypersensitivity reactions to mesalamine. Although 5-ASA agents like mesalamine are thought to be safe and are the first-line drugs for inducing remission and preventing UC [7], hypersensitivity reactions such as fever and rash occur in some patients [20]. Although aggravation of UC with mesalamine has also been reported [8,9,21–23], there have been very few reports of the changes in the endoscopic findings caused by hypersensitivity reactions. More edematous mucosa, much more purulent erosions, and ulcerations were seen. However, it is interesting that, despite some extensions of lesions to both oral and anal sides, the left-sided colon remained intact. Mesalamine-induced aggravation was diagnosed by the dramatic amelioration of symptoms after cessation of the drug, and the positive LTT result confirmed the diagnosis [24]. To the best of our knowledge, this is the first report to show changes in the endoscopic findings during mesalamine-induced hypersensitivity reactions in a case of right-sided colitis type of UC.

Conclusions

We report a rare case of right-sided colitis with mesalamine-induced aggravation with unusual overlapping clinical features.

References:

1.. Conrad K, Roggenbuck D, Laass MW, Diagnosis and classification of ulcerative colitis: Autoimmun Rev, 2014; 13; 463-66, pmid: 24424198

2.. Ordas I, Eckmann L, Talamini M, Ulcerative colitis: Lancet, 2012; 380; 1606-19, pmid: 22914296

3.. Rubin DT, Rothe JA, The peri-appendiceal red patch in ulcerative colitis: Review of the University of Chicago experience: Dig Dis Sci, 2010; 55; 3495-501, pmid: 20936357

4.. Cohen T, Pfeffer RB, Valensi Q, „Ulcerative appendicitis” occurring as a skip lesion in chronic ulcerative colitis; Report of a case: Am J Gastroenterol, 1974; 62; 151-55, pmid: 4855480

5.. Kurt EJ, Brown CH, Segmental ulcerative colitis, classification; Report of nine unusual cases: Am J Gastroenterol, 1959; 31; 419-31, pmid: 13637066

6.. Okada M, Maeda K, Yao T, Right-sided ulcerative colitis: J Gastroenterol, 1996; 31; 717-22, pmid: 8887041

7.. Ford AC, Achkar JP, Khan KJ, Efficacy of 5-aminosalicylates in ulcerative colitis: Systematic review and meta-analysis: Am J Gastroenterol, 2011; 106; 601-16, pmid: 21407188

8.. Kapur KC, Williams GT, Allison MC, Mesalazine induced exacerbation of ulcerative colitis: Gut, 1995; 37; 838-39, pmid: 8537058

9.. Sturgeon JB, Bhatia P, Hermens D, Exacerbation of chronic ulcerative colitis with mesalamine: Gastroenterology, 1995; 108; 1889-93, pmid: 7768395

10.. D’Haens G, Sandborn WJ, Feagan BG, A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis: Gastroenterology, 2007; 132; 763-86, pmid: 17258735

11.. Tremaine WJ, Is indeterminate colitis determinable?: Curr Gastroenterol Rep, 2012; 14; 162-65, pmid: 22314810

12.. Matsui T, Yao T, Sakurai T, Clinical features and pattern of indeterminate colitis: Crohn’s disease with ulcerative colitis-like clinical presentation: J Gastroenterol, 2003; 38; 647-55, pmid: 12898357

13.. Quinton JF, Sendid B, Reumaux D, Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role: Gut, 1998; 42; 788-91, pmid: 9691915

14.. Schulte-Pelkum J, Radice A, Norman GL, Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies: J Immunol Res, 2014; 2014; 185416, pmid: 24995343

15.. Mahler M, Bogdanos DP, Pavlidis P, PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease: Clin Chim Acta, 2013; 424; 267-73, pmid: 23806819

16.. Arias-Loste MT, Bonilla G, Moraleja I, Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease: Clin Rev Allergy Immunol, 2013; 45; 109-16, pmid: 23345025

17.. Stinton LM, Bentow C, Mahler M, PR3-ANCA: A promising biomarker in primary sclerosing cholangitis (PSC): PLoS One, 2014; 9; e112877, pmid: 25397578

18.. Howarth GF, Robinson MH, Jenkins D, High prevalence of undetected ulcerative colitis: Data from the Nottingham fecal occult blood screening trial: Am J Gastroenterol, 2002; 97; 690-94, pmid: 11926210

19.. Sakata T, Niwa Y, Goto H, Asymptomatic inflammatory bowel disease with special reference to ulcerative colitis in apparently healthy persons: Am J Gastroenterol, 2001; 96; 735-39, pmid: 11280543

20.. Marteau P, Nelet F, Le Lu M, Adverse events in patients treated with 5-aminosalicyclic acid: 1993–1994 pharmacovigilance report for Pentasa in France: Aliment Pharmacol Ther, 1996; 10; 949-56, pmid: 8971293

21.. Ding H, Liu XC, Mei Q, Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity: World J Gastroenterol, 2014; 20; 3716-18, pmid: 24707159

22.. Gupta MK, Pollack S, Hutchings JJ, Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion: World J Gastrointest Pharmacol Ther, 2010; 1; 132-34, pmid: 21577308

23.. Shimodate Y, Takanashi K, Waga E, Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis: Case Rep Gastroenterol, 2011; 5; 159-65, pmid: 21552438

24.. Pichler WJ, Tilch J, The lymphocyte transformation test in the diagnosis of drug hypersensitivity: Allergy, 2004; 59; 809-20, pmid: 15230812

In Press

Case report  China

Thrombolytic Therapy After Return of Spontaneous Circulation in Patients With STEMI From Medically Underdev...

Am J Case Rep In Press; DOI: 10.12659/AJCR.949976  

Case report  Greece

Multilevel Laminectomy for Lumbar Spinal Stenosis With Low Back Pain in Achondroplasia: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.950290  

Case report  Italy

Fractional CO₂ Laser (SCAR3 Scanner) for a Hypertrophic Retracting Cleft Lip Scar: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.950607  

Case report  Saudi Arabia

Postoperative Corneal Dellen Following PreserFlo MicroShunt: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.950985  

Most Viewed Current Articles

07 Dec 2021 : Case report  USA 17,691,734

Edwardsiella tarda: A Classic Presentation of a Rare Fatal Infection, with Possible New Background Risk Fac...

DOI :10.12659/AJCR.934347

Am J Case Rep 2021; 22:e934347

06 Dec 2021 : Case report  Brazil 164,491

Lipedema Can Be Treated Non-Surgically: A Report of 5 Cases

DOI :10.12659/AJCR.934406

Am J Case Rep 2021; 22:e934406

21 Jun 2024 : Case report  China (mainland) 113,090

Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...

DOI :10.12659/AJCR.944371

Am J Case Rep 2024; 25:e944371

0:00

07 Mar 2024 : Case report  USA 59,175

Neurocysticercosis Presenting as Migraine in the United States

DOI :10.12659/AJCR.943133

Am J Case Rep 2024; 25:e943133

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923